ECHO study investigates the safety & efficacy of Calquence + bendamustine + rituximab vs SoC (bendamustine + rituximab) in treatment-naïve MCL patients (n=635, over 65yrs.)
The study depicted a 27% reduction in the disease progression or death risk with an mPFS of 66.4mos. vs 49.6mos. (n=299 in each arm). The OS data (2EP) was immature with favourable trends observed
In the pre-specified analysis, carried out at the time of pandemic censoring COVID-19-related deaths, showed improved PFS of 36% across both arms with mPFS not attained vs 61.6mos. and a favourable OS trend towards the regimen
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
